

CORRESPONDENCE


Methylene Blue Is a Guanylate Cyclase Inhibitor That Does Not Interfere with Nitric Oxide Synthesis

To the Editor:

Mangelli and colleagues¹ report the life-saving effectiveness of methylene blue (MB) in treating vasoplegic syndrome in a 75-year-old man, after on-pump cardiac surgery. They present a simplified nitric oxide (NO) pathway that shows methylene blue as a nitric oxide synthase (NOS) inhibitor.

In regard to the therapeutic principles for endothelial vasoplegic dysfunction treatment associated with heart surgery, the first and most important concept concerns restrictions on the use of nonspecific inhibitors of NO synthesis (L - NMMA, L - NAME). This approach is prone to controversy, because it involves ethical issues related to the use of new therapies, besides blocking—not only iNOS, but its constitutive enzyme's (eNOS) organic form.^{2,3}

Methylene blue does not interfere with NOS and has played a longstanding beneficial role in many other clinical conditions.^{2,3} As a potent guanylyl cyclase inhibitor, MB blocks the release of cyclic guanosine monophosphate (cGMP), thereby preventing vascular smooth muscle relaxation without directly affecting NO synthesis. Nitric oxide synthase inhibitors are not currently in clinical use because of their lack of specificity in inhibiting the different NOS isoforms, with the consequent risk of generalized tissue necrosis and a higher death rate. Therefore, we suggest a modification of the diagram, to avoid restrictions upon MB on the basis of NO's detrimental microcirculatory effect:



*Paulo Roberto B. Evora, MD, PhD,
Department of Surgery and Anatomy,
Ribeirão Preto School of Medicine,
University of São Paulo,
São Paulo, Brazil*

References

1. Manghelli J, Brown L, Tadros HB, Munfakh NA. A reminder of methylene blue's effectiveness in treating vasoplegic syndrome after on-pump cardiac surgery. *Tex Heart Inst J* 2015; 42(5):491-4.
2. Evora PR, Alves Junior L, Ferreira CA, Menardi AC, Bassetto S, Rodrigues AJ, et al. Twenty years of vasoplegic syndrome

treatment in heart surgery. *Methylene blue revised. Rev Bras Cir Cardiovasc* 2015;30(1):84-92.

3. Evora PR, Ribeiro PJ, Vicente WV, Reis CL, Rodrigues AJ, Menardi AC, et al. Methylene blue for vasoplegic syndrome treatment in heart surgery: fifteen years of questions, answers, doubts and certainties. *Rev Bras Cir Cardiovasc* 2009;24(3): 279-88.

<http://dx.doi.org/10.14503/THIJ-15-5629>

This letter was sent to Dr. Joshua Manghelli, who responds in this manner:

To the Editor:

Dr. Evora is indeed correct that methylene blue inhibits guanylate cyclase¹; however, there are data to support the contention that it inhibits nitric oxide synthase as well.² We believe that the figure should be adjusted to include the inhibition of both enzymes.

*Joshua Manghelli, DO,
Indiana University School of Medicine,
Indianapolis, Indiana;
Lisa Brown, MD,
Nabil A. Munfakh, MD,
Division of Cardiothoracic Surgery,
Washington University School of Medicine,
St. Louis, Missouri; and
Hany B. Tadros, MD,
Department of Anesthesiology,
Christian Northeast Hospital,
St. Louis, Missouri*

References

1. Evora PRB. Methylene blue is a guanylate cyclase inhibitor that does not interfere with nitric oxide synthesis. *Tex Heart Inst J* 2016;43(1):103.
2. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. *Biochem Pharmacol* 1993;45(2):367-74.

<http://dx.doi.org/10.14503/THIJ-15-5685>